Endocrinology Vol. 138, No. 6 2515-2520
Copyright © 1997 by The Endocrine Society
Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) and Vasoactive Intestinal Peptide (VIP) Stimulate Interleukin-6 Production through the Third Subtype of PACAP/VIP Receptor in Rat Bone Marrow-Derived Stromal Cells
Yiqiang Cai1,
Xiaonan Xin1,
Gil-Jin Shim,
Yoko Mokuno,
Hisanori Uehara,
Takahisa Yamada,
Takashi Agui and
Kozo Matsumoto
From Institute for Animal Experimentation (Y.C., X.X.,
T.Y., K.M.), and Second Department of Pathology (H.U.), University of
Tokushima School of Medicine, Tokushima 770, and Institute for
Experimental Animal Science (G.-J.S., Y.M., T.A.), Nagoya City
University Medical School, Nagoya 467, Japan
Address all correspondence and requests for reprints to: Kozo Matsumoto, Institute for Animal Experimentation, University of Tokushima School of Medicine, Tokushima 770, Japan.
 |
Abstract
|
|---|
Regulation of Interleukin-6 (IL-6) production in bone marrow
(BM)-derived stromal cells by neuropeptides, pituitary adenylate
cyclase activating polypeptide (PACAP) and vasoactive intestinal
peptide (VIP), was examined. Both forms of PACAP, PACAP-27 and
PACAP-38, as well as VIP significantly increased IL-6 production by rat
BM-derived stromal cells at physiological concentrations ranging from
10-1010-8 M. The three related
peptides (PACAP-27, -38, and VIP) stimulated the production of both
cAMP and inositol 1,4,5-trisphosphate (IP3) in rat
BM-derived stromal cells with similar 50% effective concentrations.
The stimulatory potency of the three related peptides for the
production of IL-6, cAMP, and IP3 was almost consistent,
suggesting that the dual signaling transduction pathways may be
involved in PACAP/VIP-induced IL-6 production in rat BM-derived stromal
cells. The messenger RNA (mRNA) for the third subtype of PACAP receptor
(PVR3) was found to be abundantly expressed in both BM-derived stromal
cells and the BM tissue, whereas little of the mRNA for type 1 (PVR1)
nor type 2 (PVR2) was detected. Furthermore, the mRNAs for PACAP and
VIP were detected in the BM tissue, suggesting that both PACAP/VIP and
PVR3 are synthesized in vivo in the BM. The results shown in
this paper suggest that PACAP/VIP and their receptor play an important
role in the IL-6 production and perhaps in the hematopoiesis in the BM.
 |
Introduction
|
|---|
THE HEMATOPOIETIC and immune systems
are reported to be modulated by various neuropeptides (1, 2, 3, 4, 5, 6, 7).
Neuropeptides, such as substance P and substance K, were reported to
induce the release of interleukin (IL)-1, tumor necrosis factor-
,
and IL-6 from human blood monocytes (3). The DW/J dwarf mice, which
lack acidophilic anterior pituitary cells and are deficient in GH and
other anterior pituitary-derived hormones, were found to exhibit a
decrease in the number of peripheral blood cells including erythroid,
myeloid, and lymphoid lineages (4, 5). Recently, it was reported that
the high level of messenger RNA (mRNA) for neuropeptide Y was expressed
in B cell precursor lymphoblasts from acute lymphoblastic leukemia
patients, implying a role of neuropeptide Y in B cell development
and/or pathologic disorders of B cells (6). However, the precise roles
of individual neuropeptides in regulating hematopoietic system are not
yet elucidated.
Pituitary adenylate cyclase activating polypeptide (PACAP), recently
isolated from the ovine hypothalamus, is a neuropeptide that belongs to
the vasoactive intestinal peptide (VIP)/glucagon/secretin family (8, 9). Its mRNA was shown to be abundantly expressed in the central
nervous tissue (10, 11). Both forms of PACAP, PACAP-27 and PACAP-38,
exert their diverse biological effects by stimulating the release of
various hormones (8, 9, 12, 13, 14). The complementary DNAs (cDNAs) of
three subtypes of PACAP/VIP receptor have been cloned (15, 16, 17, 18, 19). PVR1
binds both PACAP-27 and PACAP-38 with similar affinity, but VIP with
1000-fold less affinity than PACAPs, whereas both PVR2 and PVR3 show
similar affinity for the three related peptides (15, 16, 17, 18, 19, 20).
In view of the important role of IL-6 in hematopoiesis (21, 22) and the
existence of PACAP-positive cells in the BM (23), we investigated here
a possible role of PACAP in the BM by determining the effect of
PACAP/VIP on the production of IL-6 by rat BM-derived stromal cells
in vitro. We found that the PVR3, but not the PVR1 nor PVR2,
is expressed in BM-derived stromal cells and functionally coupled to
the induction of IL-6 production via dual intracellular signaling
pathways. We discuss here a possible role of PACAP/VIP and PVR3 in the
IL-6 production and hematopoiesis in the BM.
 |
Materials and Methods
|
|---|
Materials
Experimental reagents were obtained from the following
sources: FCS, penicillin, streptomycin, and gentamicin, Life
Technologies (Grand Island, NY); PACAP-27, PACAP-38, and VIP, Peptide
Institute, Inc. (Osaka, Japan); DMEM, Nissui Pharmaceutical Co. Ltd.,
(Tokyo, Japan); oligo deoxythymidine (dT), Pharmacia, (Uppsala,
Sweden); 3-isobutyl-1-methylxanthine (IBMX) and MEM nonessential amino
acid, Sigma Chemical Co. (St. Louis, MO); Moloney-murine leukemia virus
(M-MLV) reverse transcriptase, Bethesda Research Laboratories
(Gaithersburg, MD); Taq DNA polymerase, acetylthiocholine
iodide, mouse recombinant (r) IL-3 (WAKO, Osaka, Japan); restriction
enzymes Mbo I, Takara (Kyoto, Japan); [125I]
cAMP assay kit and [3H]inositol 1,4,5-trisphosphate
(IP3) assay kit, Amersham International, (Buckinghamshire,
UK); 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine
perchlorate-labeled low-density lipoprotein (Dil-Ac-LDL), Biomedical
Technologies Inc. (Stoughton, MA).
Preparation of rat BM cells
A femoral bone was removed from a 3-month-old male F344/Tj rat.
The BM cells were isolated by flushing the bone with DMEM supplemented
with 5% FCS, 10 mM HEPES, 5.5 mM glutamine,
0.16 mM L-asparagine, 0.55 mM
L-arginine-HCl, 1x MEM nonessential amino acid, 50
µM 2-mercaptoethanol amine, 100 U/ml penicillin, 100
µg/ml streptomycin, and 25 µg/ml gentamicin [modified DMEM
(M-DMEM)] using a needle and syringe. BM cells were dispersed by
repeated pipetting, washed twice with M-DMEM, and then cultured with 25
ml of M-DMEM in an 80-cm2 flask (Nunc, Kamstrup, Denmark).
After 24 h, unattached cells were harvested and recultured for the
megakaryocyte development assay. Attached cells were continuously
cultured by adding 25 ml of fresh medium. At 3-day intervals, the old
medium and unattached cells were removed and fresh medium was added.
After 7 days in culture, stromal cells formed a confluent
monolayer.
The stromal cell population was determined by counting macrophages,
endothelial cells, and adipocytes as described previously (24).
Macrophages and endothelial cells were identified by the avidity of
Dil-Ac-LDL uptake. Both cell types were distinguished morphologically
in fluorescence-positive cells. Adipocytes were identified by staining
with Sudan III. In three independent primary cultures, contents of
macrophages, endothelial cells, and adipocytes were 10.2 ± 0.3%
(mean ± SEM), 12.4 ± 1.5% (mean ±
SEM), and <1%, respectively. In this way, other remaining
cells were determined to be fibroblastic stromal cells. For passaging,
the cells were removed with a rubber scraper, dispersed by repeated
pipetting, and then one tenth were seeded into another flask. Primary
culture cells were used for the IL-6 production assay, and passaged
culture cells were used for the detection of the PACAP and PACAPR mRNA
and cAMP production assay.
IL-6 bioassay and estimation of relative amounts of the IL-6
mRNA
Rat BM-derived stromal cells were seeded onto a 96-well
microplate at a density of 5,000/well in 200 µl of M-DMEM and
cultured overnight. On the following day, the culture medium was
aspirated, fresh medium was added, and the cells were then stimulated
with various reagents. After incubation for various periods, the
conditioned medium was removed and kept at -80 C until use. The amount
of IL-6 in the conditioned medium was estimated using an IL-6-dependent
B cell hybridoma cell line, MH60.BSF2, which was a generous gift from
Dr. K. Himeno (University of Tokushima School of Medicine) with the
permission of Dr. T. Hirano (Osaka University Medical School).
MH60.BSF2 cells were cultured for 3 d in 100 µl M-DMEM in the
presence of 10 µl stromal-cell-conditioned medium or various
concentrations of human rIL-6 (a gift from Dr. T. Hirano) as the
standard. Cell growth was estimated colorimetrically using a method
described previously (25). For estimation of relative amounts of the
IL-6 mRNA, cells were stimulated by 10-7 M
each peptide for 12 h, and the total RNA was prepared by a method
described previously (26). RT-PCR was then performed as described
previously (27).
Determination of cAMP accumulation
BM-derived stromal cells were harvested and 0.1 million cells
were incubated with PACAP-27, PACAP-38, or VIP in a volume of 0.5 ml of
M-DMEM containing 1 mM IBMX. After incubation for 30 min at
37 C, the reaction was terminated by adding 10 µl of 5% NP40
solution and boiling samples for 3 min. The reaction mixture was
centrifuged at 2,000 x g for 15 min at 4 C, and the
supernatants were removed to be used for RIAs. RIA was performed
according to the procedure supplied with the cAMP assay kit.
IP3 production assay
Cultured rat BM-derived stromal cells were suspended in M-Krebs
solution. Cells (0.1 million) were preincubated at 37 C for 5 min and
then incubated with various concentrations of PACAP-27, PACAP-38, or
VIP for various times at 37 C. The total volume of the reaction mixture
was 250 µl. The reaction was terminated by adding 250 µl of
ice-cold 15% trichloroacetic acid solution. After the tubes had been
kept on ice for 20 min, samples were centrifuged at 2,000 x
g for 20 min, and the supernatants were removed. The
supernatants were washed three times with 10 vol of
H2O-saturated diethyl ether, and the pH value was adjusted
to 7.5 with a saturated NaHCO3 solution. The amount of
IP3 was determined with an IP3 assay kit.
Detection of the mRNA for PACAP and PACAPR
Total RNA was prepared from cultured rat BM-derived
stromal cells or BM tissue according to the method described previously
(26). Two micrograms of RNA were reversely transcribed with 200 U of
M-MLV reverse transcriptase using 2 µg of oligo dT as the primer in
40 µl reaction mixture and the synthesized cDNA was used as a
template for PCR. Sense and antisense primers for PACAP were
5'-CTGTTGGTCTACGGGATAAT-3' (nucleotide 603622 of the rat PACAP cDNA)
and 5'-CTACAAGTACGCTATTCGGC-3' (nucleotide 10811100 of the rat PACAP
cDNA), respectively (28). For VIP, sense and antisense primers were
5'-GTCTCTTTAAAAGCAGACTC-3' (nucleotide 132151 of the rat VIP cDNA)
and 5'-TATGAAATTATAAGCCTTTC-3' (nucleotide 710729 of the rat VIP
cDNA), respectively (29). For PVR1, sense and antisense primers were
5'-GCCGATAGTAATTCCTTGGA-3' (nucleotide 328347 of the rat PVR1 cDNA)
and 5'-TGAATGACAGGGCATCGAGT-3' (nucleotide 10661085 of the rat PVR1
cDNA), respectively (15). For PVR2, sense and antisense primers were
5'-TGAATGACAGGGCATCGAGT-3' (nucleotide 413432 of the rat PVR2 cDNA)
and 5'-TTTGGAGCTCCAGCCCAGGA-3' (nucleotide 12991318 of the rat PVR2
cDNA), respectively (17). For PVR3, sense and antisense primers were
5'-CCCGAGGATGAGAGTAAGAT-3' (nucleotide 405424 of the rat PVR3 cDNA)
and 5'-AACAGGATCTGGTACGTGGA-3' (nucleotide 11221141 of the rat PVR3
cDNA), respectively (18). The PCR reaction mixture (100 µl) contained
100 pmol of each primer, 200 µM each of deoxynucleotides,
50 mM KCl, 10 mM Tris-HCl (pH 8.8 at room
temperature), 1.5 mM MgCl2, 0.1% Triton X-100,
5.0 U Taq DNA polymerase, and 5 µl of the above RT
product. PCR was performed with a DNA thermal cycler (Perkin Elmer
Cetus, Norwalk, CT) using 35 cycles (94 C, 1 min; 62 C, 1.5 min; 72 C,
1.5 min) for PACAP and PVR3, 35 cycles (94 C, 45 sec; 52 C, 45 sec; 72
C, 45 sec) for VIP, 35 cycles (94 C, 1 min; 60 C, 1.5 min; 72 C, 1.5
min) for PVR1, and 35 cycles (94 C, 1 min; 63 C, 1.5 min; 72 C, 1.5
min) for PVR2. After amplification, 20 µl of the PCR products were
digested by MboI in the case for checking if correct
products were amplified. PCR products were electrophoresed in a 1.2%
agarose gel for undigested PCR products or a 4% NuSieve agarose gel
for digested PCR products. After running, gels were soaked with 0.5
µg/ml ethidium bromide solution and photographed with Polaroid film
(Polaroid Corp., Cambridge, MA) under the UV light.
 |
Results
|
|---|
PACAP/VIP-induced IL-6 production by rat BM-derived stromal
cells
In order to examine whether the effect of PACAP/VIP on the IL-6
production in the BM, we stimulated rat BM-derived stromal cells by
PACAP-27, PACAP-38, and VIP. As shown in Fig. 1
, three
peptides all augmented IL-6 production by rat BM-derived stromal cells
with similar time course. Three peptides, however, had no effect on the
cell number in culture for 3 days. Figure 2
shows that
the potency of the three peptides are similar and that they exert their
effects at physiological concentrations ranging from
10-1010-8 M. The 50% effective
concentrations (EC50) for PACAP-27, PACAP-38 and VIP were
2.0 x 10-9, 6.3 x 10-10, and
8.0 x 10-10 M, respectively. In order to
show that IL-6 was certainly produced by PACAP-stimulated BM-derived
stromal cells, an increase in the steady-state level of the IL-6 mRNA
was examined in the stimulated cells. As shown in Fig. 3
, the level of IL-6 mRNA was higher in cells stimulated
by three kinds of peptides than in control cells. Furthermore,
conditioned medium of PACAP-38-stimulated stromal cells supported
megakaryocyte development in cooperation with IL-3 (data not shown),
indicating that IL-6 produced by stromal cells are also biologically
active on other cells than MH60.BSF-2 cells. PACAP was reported to
augment the IL-6 production by rat anterior pituitary cells at the
concentration of 10-10 M, whereas VIP did not
even at 10-6 M (13). We presumed that the
discrepancy in the capability of VIP in induction of IL-6 production in
the two cell types may be due to the different receptor subtypes
expressed. In order to clarify it, we examined second messengers in
PACAP/VIP-stimulated BM-derived stromal cells.

View larger version (16K):
[in this window]
[in a new window]
|
Figure 1. Stimulation of IL-6 production by PACAP-27,
PACAP-38, and VIP in rat BM-derived stromal cells. Cells were seeded
onto wells of a microtiter plate at a density of 5,000/well. After
overnight culture, the medium was aspirated, fresh medium was added,
and then cells were stimulated by 10-7 M
PACAP-27 ( ), PACAP-38 ( ), or VIP ( ) for the indicated times.
The conditioned medium was removed and assayed IL-6 concentrations
using an IL-6-dependent B cell hybridoma, MH60.BSF2, with human rIL-6
as the standard. Closed circles represent the basal
production of IL-6. Data are means ± SEM of
triplicate observations and are representative of three similar
results.
|
|

View larger version (30K):
[in this window]
[in a new window]
|
Figure 3. Comparison of relative amounts of the IL-6 mRNA in
control and stimulated stromal cells. Cells were stimulated by
10-7 M PACAP-27, PACAP-38, or VIP for 12
h, and then total RNA was prepared. Amounts of the IL-6 mRNA were
compared between control and stimulated stromal cells by performing
RT-PCR using various amplification cycles with respect to both the IL-6
and ß-actin mRNAs. This is representative of three similar results.
|
|
Second messengers of PACAP in rat BM-derived stromal cells
It has been demonstrated that the three subtypes of PACAPRs
are coupled to the activation of adenylate cyclase (15, 16, 17, 18, 19). Therefore,
the accumulation of cAMP by BM-derived stromal cells were assayed after
stimulation of PACAP-27, PACAP-38, and VIP. As shown in Fig. 4
, the three peptides evoked a significant and
dose-dependent elevation of cAMP levels. The EC50 were
approximately 4.4 x 10-9, 6.6 x
10-10, and 3.3 x 10-9 M for
PACAP-27, PACAP-38, and VIP, respectively. The three peptides were all
effective to the augmentation of cAMP production, although their
potency was slightly different; PACAP-38 was 5- to 6-fold more potent
than VIP. These results suggest that PACAPR on rat BM-derived stromal
cells are either PVR2 or PVR3, because PVR1 was reported to bind VIP
with 1,000-fold less affinity than two forms of PACAP (15, 16). Because
it has been shown that the third subtype of PACAPR recently discovered,
PVR3, is coupled to the phospholipase C (PLC) activation (19) but PVR2
is unknown (17), we further examined whether PACAP and VIP are capable
of stimulating PLC in BM-derived stromal cells. As shown in Fig. 5A
, IP3 was rapidly produced by the
stimulation of PACAP-27, PACAP-38, and VIP with a peak at 1530 sec
after addition of each peptide. The rapid increase in IP3
production within 30 sec is consistent with the previous report (30).
The potency of the three peptides on the stimulation of IP3
production was similar each other (Fig. 5B
). The EC50 were
4.8 x 10-10, 1.2 x 10-10, and
3.0 x 10-10 M for PACAP-27, PACAP-38,
and VIP, respectively. It is, therefore, proposed that PACAPR on rat
BM-derived stromal cells seems to be the third type of PACAPR. In order
to clarify it, the PACAPR mRNA expressed in rat BM-derived stromal
cells are examined by RT-PCR using each PACAPR-specific primers.
Expression of the PVR3 mRNA in BM-derived stromal cells and the BM
tissue
We examined expression of PACAPRs by RT-PCR with three pairs
of primers, which were unique to the rat PVR1, PVR2, and PVR3. Primers
were synthesized according to information of the rat cDNA sequences
(15, 17, 18). We clearly detected the abundant expression of mRNA for
PVR3 in cultured BM-derived stromal cells comparable to that of the
brain (Fig. 6
). In contrast to PVR3, little expression
of PVR1 nor PVR2 was detected in the BM-derived stromal cells, although
expression of them in the brain was well observed. That the PCR
certainly amplified respective PACAPR mRNAs was corroborated by
digestion analysis with restriction enzyme, MboI (data not
shown). In order to test whether the PVR3 is expressed in
vivo, we isolated the total RNA from the rat BM tissue and used it
for the RT-PCR and MboI digestion experiments. The data
showed the same result as in cultured cells (data not shown),
suggesting that PVR3 is only expressed in the rat BM in
vivo.

View larger version (28K):
[in this window]
[in a new window]
|
Figure 6. Detection of the mRNA for PVR3 in rat BM-derived
stromal cells. Total RNA was prepared from the BM-derived stromal cells
and rat whole brain. RT-PCR was performed using PCR primers unique to
three subtypes of PACAPRs. Lanes 1, rat BM-derived stromal cells; 2,
rat brain. This is representative of four similar results.
|
|
Expression of the mRNA for PACAP and VIP in the BM tissue
The fact that the physiological concentrations
(10-9 M) of PACAPs and VIP up-regulate the
production of IL-6 by BM-derived stromal cells raised a question as
whether there exists the endogenous ligands in the BM. To examine this
possibility, we attempted to detect the mRNAs for PACAP and VIP by
RT-PCR. Figure 7
shows that the mRNAs for PACAP and VIP
are expressed in the BM tissue. That the resulting PCR products were
specific for PACAP and VIP was confirmed by MboI digestion
(data not shown). These results support the previous report showing the
existence of PACAP-positive cells in rat BM tissue (23) and suggest
that the PACAP/VIP/PVR3 ligand-receptor system plays a physiological
role in producing IL-6 in the BM.

View larger version (16K):
[in this window]
[in a new window]
|
Figure 7. Detection of the mRNA for PACAP and VIP in the rat
BM tissue. Lanes 1, rat BM tissue; 2, rat brain. This is representative
of two similar results.
|
|
 |
Discussion
|
|---|
The role of IL-6 on hematopoiesis has been well investigated
(21, 22). It is proposed that IL-6 may be one of the factors capable of
inducing entry of primitive stem cells into cell cycle and that IL-6
may act as a competence factor that is required to confer
responsiveness to the classical hematopoietic growth factors. The
regulation of IL-6 production and secretion by stromal cells in the BM
has not been completely elucidated. IL-1, transforming growth
factor-ß, and tumor necrosis factor-
were reported to be inducers
of IL-6 production by a murine BM-derived stromal cell clone (31).
Recently, hormonal and/or neuronal regulation of cytokine production
has been noted in other immune tissues. However, little is known about
hormonal or neuronal regulation of cytokine production in the BM. We
report here that neuropeptides PACAPs and VIP, which were already
reported to be secretagogues for IL-6 in anterior pituitary cells (13, 14, 32), also induce IL-6 production in rat BM-derived stromal cells
(
Figs. 13

). We also demonstrated the existence of receptors for
PACAP/VIP, which are coupled to the activation of both adenylate
cyclase and PLC (Figs. 4
and 5
). Furthermore, we could show evidence
that endogenous ligands PACAP and VIP were synthesized in the BM tissue
(Fig. 7
). These results suggest that the PACAP/VIP and their receptor
system plays a physiological role in regulating IL-6 production in the
BM. Recently, the calcitonin gene-related peptide was shown to increase
dose-dependently cAMP and IL-6 production in a murine BM-derived
stromal cell line (7). Furthermore, we recently showed that endothelin,
a potent vasoactive polypeptide, also plays a role in the regulation of
IL-6 production by rat BM-derived stromal cells (24). Taken together,
it is thus raised the possibility that multiple neuro-hormonal factors
may be involved in hematopoiesis by controlling the production of IL-6
in the BM.
The cDNAs for three subtypes of PACAPR have been cloned so far.
The type 1 receptor, PVR1, preferentially binds two forms of PACAP,
PACAP-27 and PACAP-38, and binds VIP with 1,000-fold less affinity than
PACAPs (15, 16). Furthermore, the PVR1 was reported to be coupled to
the activation of both adenylate cyclase and PLC (33). The type 2
receptor, PVR2, was originally identified as the receptor for VIP, but
was shown to bind two forms of PACAP as well as VIP. The PVR2 was shown
to be coupled to the adenylate cyclase activation, but it is unknown if
it is coupled to the PLC activation (17). Recently, the third type of
PACAPR, PVR3, was identified, which also binds two forms of PACAP and
VIP with similar affinity (18, 19). The PVR3 was also shown to be
coupled to the adenylate cyclase activation. The coupling to the PLC
activation of the PVR3 was indirectly demonstrated by eliciting a
Ca2+ influx by PACAPs and VIP in Xenopus oocytes
expressed this receptor (19). With respect to the induction of IL-6
production by BM-derived stromal cells, two forms of PACAP and VIP were
equipotent. Furthermore, the three peptides stimulated both adenylate
cyclase and PLC in these cells. These results suggest that the PVR3 may
be responsible to the induction of IL-6 production in these cells. To
clarify it, expression of the three subtypes of PACAPR mRNA was
examined by RT-PCR using primers unique to the respective PACAPR
subtypes. The result shows that BM-derived stromal cells express the
PVR3 only, indicating that the PVR3 is responsible to the induction of
IL-6 by BM-derived stromal cells in response to PACAPs or VIP.
With respect to the role of PACAP/VIP in regulating IL-6
production, it is very interesting to compare our results in the BM
with those in the anterior pituitary gland. Firstly, in the anterior
pituitary IL-6 was regarded to be a stimulator for the secretion of
various anterior pituitary hormones (34). Secondly, it has been shown
that IL-6 is produced in the anterior pituitary in situ in
response to PACAP/VIP as well as inflammatory cytokines (13, 32, 35, 36). Finally, it has been evidenced that agranular hormone-nonsecreting
folliculo-stellate (FS) cells produce IL-6 in the anterior pituitary
(14, 37). A role of FS cells in the pituitary may be analogous to that
of stromal cells in the BM. Both types of cells secrete IL-6 in
response to various stimulations, including PACAP/VIP. IL-6 is regarded
to play a particular role in both tissues; in stimulating the release
of pituitary hormones in the pituitary and in supporting the growth and
differentiation of hematopoietic cells in the BM. However, with respect
to the potency of PACAPs and VIP, there exists discrepancy in the two
tissues. In the pituitary, the effect of VIP is controversial. Thus,
VIP was reported to be as potent as PACAPs in cAMP production but much
less potent than PACAPs in IL-6 production (14). In other report, VIP
is as potent as PACAPs in IL-6 production (32). This may be due to the
existence of multiple PACAPR subtypes and multiple target cells for
PACAP/VIP in the pituitary. In fact, cDNAs of both PVR1 and PVR3 were
cloned from the same rat anterior pituitary mRNA pool (16, 18).
In contrast, BM-derived stromal cells were shown to express the
PVR3 only by very specific RT-PCR analysis. Cultured BM-derived stromal
cells are heterogenous consisted by fibroblastic cells, macrophages,
endothelial cells, and adipocytes. Nevertheless, the fact that stromal
cells express the PVR3 only may suggest that the target of PACAP/VIP
may be a single type of cells. PACAPR subtypes were reported to
localize in various tissues. However, it is noteworthy to find that the
BM tissue express the PVR3 only. It should be interesting that only the
PVR3 plays a role in regulating hematopoiesis in the BM through
regulating IL-6 production by BM stromal cells. Although we showed in
this report that the ligands, PACAP and VIP were also synthesized in
the BM, it should be necessary to clarify the cell type synthesizing
the ligands in situ, in order to fully understand roles of
PACAP/VIP in the BM.
 |
Acknowledgments
|
|---|
We thank Drs. K. Himeno and T. Hirano for IL-6-dependent cell
line, MH60.BSF2 and human rIL-6.
 |
Footnotes
|
|---|
1 Present address: Department of Medicine and Molecular Genetics
(Y.C.) and Department of Molecular Pharmacology (X.X.), Albert Einstein
School of Medicine, Bronx, New York 10467. 
Received September 9, 1996.
 |
References
|
|---|
-
Payan DG, Brewster DR, Goetzl EJ 1983 Specific
stimulation of human T lymphocytes by substance P. J Immunol 131:16131615[Abstract]
-
ODorisio MS, Wood CL, ODorisio TM 1985 Vasoactive intestinal peptide and neuropeptide modulation of the immune
response. J Immunol 135:792s796s
-
Lotz M, Vaughan JH, Carson DA 1988 Effect of
neuropeptides on production of inflammatory cytokines by human
monocytes. Science 241:12181220[Abstract/Free Full Text]
-
Murphy WJ, Durum SK, Anver MR, Longo DL 1992 Immunologic and hematologic effects of neuroendocrine hormones: Studies
on DW/J Dwarf mice. J Immunol 148:37993805[Abstract]
-
Murphy WJ, Durum SK, Longo DL 1992 Role of
neuroendocrine hormones in murine T cell development: Growth hormone
exerts thymopoietic effects in vivo. J Immunol 149:38513857[Abstract]
-
Kogner P, Ericsson A, Barbany G, Persson H, Theodorsson
E, Björk O 1992 Neuropeptide Y (NPY) synthesis in
lymphoblasts and increased plasma NPY in pediatric B-cell precursor
leukemia. Blood 80:13241329[Abstract/Free Full Text]
-
Sakagami Y, Girasole G, Yu X-P, Boswell HS, Manolagas
SC 1993 Stimulation of interleukin-6 production by either
calcitonin gene-related peptide or parathyroid hormone in two
phenotypically distinct bone marrow-derived murine stromal cell lines.
J Bone Miner Res 8:811816[Medline]
-
Miyata A, Arimura A, Dahl RR, Minamino N, Uehara
A, Jiang L, Culler MD, Coy DH 1989 Isolation of a novel 38
residue-hypothalamic polypeptide which stimulates adenylate cyclase in
pituitary cells. Biochem Biophys Res Commun 164:567574[CrossRef][Medline]
-
Miyata A, Jiang L, Dahl RD, Kitada C, Kubo K, Fujino M,
Minamino N, Arimura A 1990 Isolation of a neuropeptide
corresponding to the N-terminal 27 residues of the pituitary adenylate
cyclase activating polypeptide with 38 residues (PACAP38). Biochem
Biophys Res Commun 170:643648[CrossRef][Medline]
-
Arimura A, Somogyv
ri-Vigh A, Miyata A, Mizuno K,
Coy DH, Kitada C 1991 Tissue distribution of PACAP as determined
by RIA: Highly abundant in the rat brain and testes. Endocrinology 129:27872789[Abstract]
-
Köves K, Arimura A, Somogyv
ri-Vigh A, Vigh
S, Miller J 1990 Immunohistochemical demonstration of a novel
hypothalamic peptide, pituitary adenylate cyclase activating
polypeptide, in the ovine hypothalamus. Endocrinology 127:264271[Abstract]
-
Watanabe T, Masuo Y, Matsumoto H, Suzuki N, Ohtaki T,
Masuda Y, Kitada C, Tsuda M, Fujino M 1992 Pituitary adenylate
cyclase activating polypeptide provokes cultured rat chromaffin cells
to secrete adrenalin. Biochem Biophys Res Commun 182:403411[CrossRef][Medline]
-
Tatsuno I, Somogyvari-Vigh A, Mizuno K, Gottschall PE,
Hidaka H, Arimura A 1991 Neuropeptide regulation of interleukin-6
production from the pituitary: Stimulation by pituitary adenylate
cyclase activating polypeptide and calcitonin gene-related peptide.
Endocrinology 129:17971804[Abstract]
-
Matsumoto H, Koyama C, Sawada T, Koike K, Hirota K,
Miyake A, Arimura A, Inoue K 1993 Pituitary
folliculo-stellate-like cell line (TtT/GF) responds to novel
hypophysiotropic peptide (pituitary adenylate cyclase-activating
peptide), showing increased adenosine 3',5'-monophosphate and
interleukin-6 secretion and cell proliferation. Endocrinology 133:21502155[Abstract]
-
Pisegna JR, Wank SA 1993 Molecular cloning and
functional expression of the pituitary adenylate cyclase-activating
polypeptide type I receptor. Proc Natl Acad Sci USA 90:63456349[Abstract/Free Full Text]
-
Morrow JA, Lutz EM, West KM, Fink G, Harmar AJ 1993 Molecular cloning and expression of a cDNA encoding a receptor for
pituitary adenylate cyclase activating polypeptide (PACAP). FEBS Lett 329:99105[CrossRef][Medline]
-
Ishihara T, Shigemoto R, Mori K, Takahashi K, Nagata
S 1992 Functional expression and tissue distribution of a novel
receptor for vasoactive intestinal polypeptide. Neuron 8:811819[CrossRef][Medline]
-
Lutz EM, Sheward WJ, West KM, Morrow JA, Fink G, Harmar
AJ 1993 The VIP2 receptor: molecular characterization
of a cDNA encoding a novel receptor for vasoactive intestinal peptide.
FEBS Lett 334:38[CrossRef][Medline]
-
Inagaki N, Yoshida H, Mizuta M, Mizuno N, Fujii Y, Gonoi
T, Miyazaki JI, Seino S 1994 Cloning and functional
characterization of a third pituitary adenylate cyclase-activating
polypeptide receptor subtype expressed in insulin-secreting cells. Proc
Natl Acad Sci USA 91:26792683[Abstract/Free Full Text]
-
Rawlings SR, Hezarth M 1996 Pituitary adenylate
cyclase-activating polypeptide (PACAP) and PACAP/vasoactive intestinal
polypeptide receptors: actions on the anterior pituitary gland. Endocr
Rev 17:429[CrossRef][Medline]
-
Van Snick J 1990 Interleukin-6: An overview. Annu
Rev Immunol 8:253278[Medline]
-
Akira S, Hirano T, Taga T, Kishimoto T 1990 Biology
of multifunctional cytokines: IL 6 and related molecules (IL 1 and
TNF). FASEB J 4:28602867[Abstract]
-
Gaytan F, Martinez-Fuentes AJ, Garcia-Navarro F, Vaudry
H, Aguilar E 1994 Pituitary adenylate cyclase-activating peptide
(PACAP) immunolocalization in lymphoid tissues of the rat. Cell Tissue
Res 276:223227[Medline]
-
Agui T, Xin X, Cai Y, Sakai T, Matsumoto K 1994 Stimulation of interleukin-6 production by endothelin in rat bone
marrow-derived stromal cells. Blood 84:25312538[Abstract/Free Full Text]
-
Mosmann T 1983 Rapid colorimetric assay for
cellular growth and survival: Application to proliferation and
cytotoxicity assays. J Immunol Meth 65:5563[CrossRef][Medline]
-
Chomczynski P, Sacchi N 1987 Single-step
method of RNA isolation by acid guanidinium
thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156159[Medline]
-
Xin X, Cai Y, Matsumoto K, Agui T 1995 Endothelin-induced interleukin-6 production by rat aortic endothelial
cells. Endocrinology 136:132137[Abstract]
-
Ogi K, Kimura C, Onda H, Arimura A, Fujino M 1990 Molecular cloning and characterization of cDNA for the precursor
of rat pituitary adenylate cyclase activating polypeptide (PACAP).
Biochem Biophys Res Commun 173:12711279[CrossRef][Medline]
-
Nishizawa M, Hayakawa Y, Yanaihara N, Okamoto H 1985 Nucleotide sequence divergence and functional constraint in VIP
precursor mRNA evolution between human and rat. FEBS Lett 183:5559[CrossRef][Medline]
-
Isobe K, Nakai T, Takuwa Y 1993 Ca2+-dependent stimulatory effect of pituitary adenylate
cyclase-activating polypeptide on catecholamine secretion from cultured
porcine adrenal medullary chromaffin cells. Endocrinology 132:17571765[Abstract]
-
Gimble JM, Hudson J, Henthorn J, Hua X, Burstein SA 1991 Regulation of interleukin 6 expression in murine bone marrow
stromal cells. Exp Hematol 19:10551060[Medline]
-
Spangelo BL, Isakson PC, MacLeod RM 1990 Production
of interleukin-6 by anterior pituitary cells is stimulated by increased
intracellular adenosine 3',5'-monophosphate and vasoactive intestinal
peptide. Endocrinology 127:403409[Abstract]
-
Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert
J, Seeburg PH, Journot L 1993 Differential signal transduction by
five splice variants of the PACAP receptor. Nature 365:170175[CrossRef][Medline]
-
Spangelo BL, Judd AM, Isakson PC, MacLeod RM 1989 Interleukin-6 stimulates anterior pituitary hormone release in
vitro. Endocrinology 125:575577[Abstract]
-
Spangelo BL, MacLeod RM, Isakson PC 1990 Production
of interleukin-6 by anterior pituitary cells in vitro.
Endocrinology 126:582586[Abstract]
-
Spangelo BL, Judd AM, Isakson PC, MacLeod RM 1991 Interleukin-1 stimulates interleukin-6 release from rat anterior
pituitary cells in vitro. Endocrinology 128:26852692[Abstract]
-
Vankelecom H, Carmeliet P, Van Damme J,
Billiau A, Denef C 1989 Production of interleukin-6 by
folliculo-stellate cells of the anterior pituitary gland in a
histiotypic cell aggregate culture system. Neuroendocrinology 49:102106 [Medline]
This article has been cited by other articles:

|
 |

|
 |
 
N. El Zein, B. Badran, and E. Sariban
VIP differentially activates {beta}2 integrins, CR1, and matrix metalloproteinase-9 in human monocytes through cAMP/PKA, EPAC, and PI-3K signaling pathways via VIP receptor type 1 and FPRL1
J. Leukoc. Biol.,
April 1, 2008;
83(4):
972 - 981.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. M. Sherwood, S. L. Krueckl, and J. E. McRory
The Origin and Function of the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)/Glucagon Superfamily
Endocr. Rev.,
December 1, 2000;
21(6):
619 - 670.
[Abstract]
[Full Text]
|
 |
|